A 2023 ACMG review and clinical guidance for CHEK2 heterozygotes2 noted a single publication of non-significant CHEK2-associated bladder cancer23 but deemed this evidence insufficient to make recommendations; more recent publications have found additional evidence of a CHEK2-bladder cancer association.24,25 Genomic ascertainment in this study revealed similarly increased bladder cancer risk in both cohorts (especially in PTV). This evidence concerns the gene CHEK2 and urinary bladder cancer.